Eyebright Medical(SH:688050) Xin Lang Cai Jing·2025-09-02 06:05Core Viewpoint - Aibo Medical's stock has experienced fluctuations, with a year-to-date decline of 12.36% and recent gains over the past few trading days, indicating potential volatility in the market [1][2]. Company Overview - Aibo Medical, established on April 21, 2010, and listed on July 29, 2020, specializes in the research, production, and sales of ophthalmic medical devices [2]. - The company's revenue composition includes: 43.86% from artificial lenses, 30.06% from contact lenses, 15.14% from orthokeratology lenses, 6.01% from other myopia control products, 2.37% from other surgical products, 1.62% from other vision care products, and 0.95% from other income [2]. Financial Performance - For the first half of 2025, Aibo Medical reported a revenue of 787 million yuan, representing a year-on-year growth of 14.72%, and a net profit attributable to shareholders of 213 million yuan, with a growth of 2.53% [2]. - The company has distributed a total of 241 million yuan in dividends since its A-share listing, with 173 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, Aibo Medical had 15,400 shareholders, an increase of 58.37% from the previous period, with an average of 12,301 circulating shares per shareholder, a decrease of 36.86% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Hua Bao Zhong Zheng Medical ETF, with notable changes in their holdings [3].